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Abstract
Purpose Population pharmacokinetic analyses (PPK) have
been used to establish bioequivalence for small molecules
and some biologicals. We investigated whether PPK could
also be useful in biosimilarity testing for monoclonal antibod-
ies (MAbs).
Methods Data from a biosimilarity trial with two trastuzumab
products were used to build population pharmacokinetic
models. First, a combinedmodel was developed and similarity
between test and reference product was evaluated by
performing a covariate analysis with trastuzumab drug prod-
uct (test or reference) on all model parameters. Next, two
separate models were developed, one for each drug product.
The model structure and parameters were compared and eval-
uated for differences.
Results Drug product could not be identified as statistically
significant covariate on any parameter in the combinedmodel,
and the addition of drug product as covariate did not improve
the model fit. A similar structural model described both the
test and reference data best. Only minor differences were
found between the estimated parameters from these separate
models.
Conclusions PPK can also be used to support a biosimilarity
claim for a MAb. However, in contrast to the standard non-
compartmental analysis, there is less experience with a PPK
approach. Here, we describe two methods of how PPK can be
incorporated in biosimilarity testing for complex therapeutics.
Keywords Biosimilarity . Population pharmacokinetic
modelling . Pharmacokinetics . Biological . Trastuzumab .
Non-linear kinetics
Introduction
During the past decades, many biotherapeutics have been
marketed, mostly for use in the field of oncology and rheuma-
tology. Although efficacious, high costs often limit the avail-
ability of these therapies or greatly burden the health care
system. For example, treatment of a rheumatologic US patient
with biologics costs on average $20,000 to $30,000 annually
[1], and a single cycle of bevacizumab or other monoclonal
antibody (MAb) can cost $2000 or more [2]. In 2014, the top
20 in global medicinal product sales contained 10
biotherapeutics, generating revenues between 4.4 and 11.8
billion dollar each [3]. Because of the growing number of
patent expirations for the original biotherapeutics, it is expect-
ed that research of biosimilars will increase.
A first requirement for registration of the novel compound
is to establish pharmacokinetic ‘biosimilarity’. Although the
terminology slightly differs between the regulatory agencies,
all agree on the basic concept of biosimilarity, which is that the
novel (‘test’) compound should be highly similar to its origi-
nator (‘reference’) in terms of quality, efficacy and safety and
that any remaining difference should be clinically insignifi-
cant [4–6].
Notwithstanding specific criteria for biotherapeutics, often,
parts of guidelines for establishing bioequivalence—not
biosimilarity—between chemically derived substances
(‘small molecules’) are applied. These guidelines require that
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similarity should be demonstrated for key pharmacokinetic
parameters, most commonly area under the concentration-
time curve (AUC) and maximum concentration (Cmax), based
on predefined acceptance limits at the highest dose level used.
According to an evaluation by theWorld Health Organisation,
studies proving biosimilarity generally use the 80–125 %
equivalence range due to lack of specific acceptance criteria
for biotherapeutics [4].
Although it is widely recognised that a non-compartmental
analysis (NCA) is less appropriate when dealing with complex
pharmacokinetics, it is still the most commonly used analyti-
cal method for demonstrating biosimilarity. Mentré’s group
has extensively studied the use of population pharmacokinetic
techniques in bioequivalence testing and found that it yielded
similar results, with the modelling approach leading to a better
understanding of the underlying biological system and the
NCA being a relatively easy approach that does not require
modelling and whose results can be used in a statistical anal-
ysis. The same was found for two biologicals, somatropin and
epoetin-α [7–9].
We investigated whether a population pharmacokinetic anal-
ysis (PPK) could also be useful in bioequivalence testing for
monoclonal antibodies (MAbs), which display complex elimi-
nationmechanisms, including non-linear routes, and have a plas-
ma half-life of one to multiple weeks. Two approaches in model-
ling PK data were studied. First, we developed a combinedmod-
el built on all available data for both the test and reference prod-
uct and tested whether adding product (test/reference) as a co-
variate would improve the model, indicating non-similarity.
Second, we developed separate models, one for test and one
for reference product. This approach does not assume similarity
as a starting point and allows comparison of the model structures
and parameters. For this exercise, we chose the humanisedMAb
trastuzumab, which targets the HER2 receptor.
Methods
Study population and treatment
Data was gathered in a phase I randomised, single-dose, par-
allel group bioequivalence study, preceded by a placebo-
controlled dose escalation part [10]. In this study, 110 male
volunteers, aged 18–45 years, who were deemed healthy after
a full medical screening, received trastuzumab in 250 mL
0.9 % NaCl as an intravenous infusion over 90 min. Two
trastuzumab products were administered: the biosimilar prod-
uct (test, T), codenamed FTMB (Synthon BV, Nijmegen,
The Netherlands) and the EU-licenced product (reference,
R), marketed as Herceptin®.
Studied dose levels of the test product in the dose escalation
part were 0.5 mg/kg (n = 6), 1.5 mg/kg (n = 6) and 3 mg/kg
(n = 6). The bioequivalence part consisted of 92 participants,
who randomly received test (n = 46) or reference (n = 46)
product at 6 mg/kg.
Based on the trastuzumab content of the used test and
reference product vials, the actual dose levels were deter-
mined to be 0.49, 1.48, 2.96 and 5.96 mg/kg for T and
6.44 mg/kg for R.
Bioanalyses
Trastuzumab was quantitated in serum samples collected pre-
dose and at 45 min, 1.5 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h and 24 h,
and at 2, 4, 8, 14, 21, 28, 35, 42, 49 and 63 days after start of
administration. A detailed description of the assay is given by
Wisman [10]. The lower limit of quantification (LLOQ) was
0.060 μg/mL. All pre-dose trastuzumab concentrations
<LLOQ were set to zero prior to analysis. Post-dose concen-
trations below LLOQ were not included. A serum sample for
the quantification of serumHER2 extracellular domain (ECD)
was collected prior to administration. This assay had a LLOQ
of 0.50 ng/mL.
In the original clinical study protocol, the sample at day 63
was not collected for PK analysis and hence not included in
the previously reported NCA results [10]. However, as this
sample provided valuable insight in the non-linear clearance




Population pharmacokinetic analysis (PPK) followed a step-
wise approach. First, a general model for trastuzumab, here-
after referred to as ‘combined model’, was developed based
on all available PK data for both test and reference product,
including dose levels of the dose escalation part (0.49, 1.48
and 2.96 mg/kg). To investigate potential bias in the PK
models due to analysing test and reference products simulta-
neously, PK models were also developed for the test (model
T) and reference product (model R) separately and included
only data from subjects who were exposed to 6 mg/kg test or
reference product. These are hereafter referred to as ‘separate
models’. The separate models were developed in parallel in
order to maintain a structurally similar model for the test and
reference product. Consequently, the model was only adopted
if the corresponding model in the other treatment arm was
preferred over its parent as well.
Model development
Model development was performed using non-linear mixed
effects modelling (NONMEM 7.2.0, Icon Development
Solutions, Ellicott City, MD, USA) and closely followed the
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FDA and EMA guidelines for PPK [11, 12]. Models were
built under ADVAN 13 with tolerance (TOL) 9, and the
first-order conditional method with interaction (FOCE-I)
was used for parameter estimation. NONMEM reports an ob-
jective function value (OFV), which is the −2·log likelihood.
Model hypothesis testing used the likelihood ratio test under
the assumption that the difference in OFV is chi-square dis-
tributed with degrees of freedom being determined by the
number of additional parameters in the more complex model.
Hence, with a decrease in OFVof ≥7.88 points (p < 0.005), the
model is preferred over its parent model. Also, model perfor-
mance was evaluated by means of goodness-of-fit plots, using
the software package R.
Several structural models with two or three compartments
including combinations of linear and non-linear clearance
were fitted to the data to determine the best structural model.
Log-normal distribution of the between-subject variability (η)
was assumed, and several residual error (ε) structures were
tested (proportional, additive and combined).
Potential covariate correlations, defined as a significant
Pearson’s product-moment correlation coefficient (p < 0.01
and r2 > 0.5), were tested in the model development, in linear
and exponential manners, and incorporated based on improve-
ment in model performance. Explored covariates included
lean body weight (LBW) [13], weight (WT), body surface
area (BSA) [14], height (HT), BMI, age, HER2 ECD concen-
tration, dose and product.
Model evaluation and predictive performance
To evaluate the robustness and predictive performance of the
developed model, a visual predictive check (VPC) with 500
simulations was performed [15]. Prediction intervals of 95 %
were obtained by simulating the model results from the orig-
inal data. Model evaluation was performed by calculating the
coefficient of variation to derive the uncertainty in the param-
eter estimates of the model which was considered acceptable
when lower than 50 %. Also, shrinkage, as defined by
Karlsson [16], was calculated to exclude model
misspecification; shrinkage less than 30 % was considered
acceptable.
Individual pharmacokinetic profiles
Individual pharmacokinetic profiles were simulated in R
(version 3.2.2, R foundation for statistical computing,
Vienna Austria) using the individual participant’s model
parameter estimates. Integration was performed from the start
of administration until the time point when the concentration
in the central compartment dropped below 0.01 μg/mL. For
the simulations, the following integration intervals were used:
1 s from administration until 24 h, 1 min until day 80 and
1 day thereafter. The concentrations were stored at original
sampling times and at every 5 min. Trastuzumab concentra-
tion at the start of administration was assumed to be 0 μg/mL.
Comparison to NCA
For comparison to a standard NCA, AUCs were derived using
model simulated (predicted) individual concentrations at the
original sampling times. AUC from administration (time 0) to
the time of the last concentration > LLOQ (AUClast) was cal-
culated using the linear trapezoidal method. AUC extrapolated
to infinity (AUCinf) based on the apparent terminal elimina-
tion rate constant was calculated as well.
Biosimilarity statistics were performed on AUCinf or
AUClast of all participants who were exposed to 6 mg/kg,
comparing T to R in an unpaired t test, using the software
package R. AUCs were natural log (ln)-transformed prior to
statistical analysis. The estimated difference in means and the
corresponding 90 % confidence interval (CI) were back-trans-
formed to obtain the relative geometric mean ratio (GMR) of
T over R (T/R). These results were then compared to those
calculated in a standard NCA.
To correct for the difference between actual (5.96 and
6.44 mg/kg) and labelled dose (6 mg/kg), a linear normalisa-
tion to 6 mg/kg was applied to the individual AUCs in the
NCA. In the PPK, individual profiles were simulated with the
actual and labelled dose. Both corrected and uncorrected
AUCs were calculated and statistically compared.
Results
Population
Pharmacokinetic data were gathered from 110 healthy male
volunteers, whose demographics are presented in Table 1. In
total, 1247 serum trastuzumab concentrations were available
for the test product (T), of which 143 were <LLOQ (64 pre-
dose). In the 6 mg/kg test group, 60/906 observations were
<LLOQ (46 pre-dose) and for the reference product
(Herceptin®), 51/912 observations (44 pre-dose).
Model development
First step: combined model
Initial exploration of the data suggested that a two- or three-
compartment model would describe the data best. Based on
the observed non-linear kinetics, Michaelis-Menten kinetics
was incorporated, described in terms of maximum rate of
elimination (Vmax), and the concentration where ½·Vmax is
reached (KM). Addition of a linear elimination pathway, de-
fined by elimination rate constant (ke), significantly improved
the model fit for both the two- and three-compartment model.
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Adding the third compartment accounted for a delayed
clearance effect . The three-compartment model ,
parameterised in terms of a central (V1) and peripheral vol-
umes (V2, V3) of distribution and inter-compartmental clear-
ances (Q1, Q2), resulted in a significant improvement com-
pared to the two-compartment model. This was confirmed by
an improved goodness-of-fit, especially for the lower doses of
trastuzumab. Thus, the three-compartment model was consid-
ered superior over the two compartmental models (Fig. 1). A
combined residual error structure (ε) proved best fit for
purpose.
After identification of the structural model, individual esti-
mates of random effects for between-subject variability were
identified for the parameters V1, KM and ke, with final coeffi-
cient of variation values of 14.8, 35.9 and 17.2 %, respective-
ly. The residual coefficient of variation of the best model was
14.98 %. An omega block was required to correct for the
parameter correlation between KM and ke in the model.
Significant correlations were found between lean body
weight (LBW), body weight (WT), body surface area
(BSA), height (HT) and body mass index (BMI) vs. V1, with
correlation coefficients of 0.61, 0.55, 0.60, 0.54 and 0.28,
respectively. Linear regression analysis of LBW vs. BSA
resulted in a coefficient of 1 and for LBW vs. WT in 0.96.
Furthermore, significant correlation coefficients were ob-
served between BMI and ke (0.60), between serum concentra-
tions HER2 ECD and ke (0.29), and between serum concen-
trations HER2 ECD and KM (0.18).
Implementing LBW as a linear covariate on V1 (Online
Resource Eq. 1) significantly improved the objection function
value (OFV) and was added to the model. Incorporating other
weight-related covariates (WT, HTand BMI) separately in the
model did not result in a significant improvement compared to
LBW; accordingly, they were not implemented in the model.
Covariate analyses identified BMI as the one most significant-
ly correlated to ke. Incorporating this covariate linearly on ke
(Online Resource Eq. 2) further improved the model, and BMI
was thus added to the model. Incorporating HER2 ECD as a
covariate did not improve the model fit. Interestingly, the
model favours lean body weight as a size descriptor to scale
trastuzumab dose compared to body weight, which is used
clinically in dose calculation.
Adding trastuzumab drug product (test or reference) as a
covariate to the model did not explain any relevant variability.
A maximum decrease in OFVof only 5.80 points (p > 0.01)












Fig. 1 Schematic representation of the structural PK model with a
parallel linear and non-linear elimination pathway. Linear elimination is
described by an elimination rate constant (ke), and non-linear elimination
is calculated as Vmax C / (KM + C) in which Vmax is the maximum rate of
elimination, KM is the concentration which produces half of the Vmax and
C is the concentration. V1, V2 and V3 are the distribution volumes; Q1
and Q2 are the inter-compartmental clearances to the peripheral
compartments
Table 1 Demographics
Test 0.5 mg/kg Test 1.5 mg/kg Test 3.0 mg/kg Test 6.0 mg/kg Reference 6.0 mg/kg
Parameter (n = 6) (n = 6) (n = 6) (n = 46) (n = 46)
Age (year) 26.9 (8.9) 33.0 (9.1) 23.4 (2.3) 26.0 (7.3) 24.1 (5.8)
Height (cm) 183 (12.0) 176 (6.5) 184 (3.3) 184 (7.5) 182 (6.2)
Weight (kg) 73.1 (12.6) 73.0 (8.7) 72.0 (7.5) 79.5 (11.2) 77.1 (10.2)
BMI (kg/m2) 21.7 (3.3) 23.5 (2.6) 21.2 (2.1) 23.4 (2.5) 23.2 (2.7)
Lean body weight (kg) 59.4 (8.4) 57.5 (5.1) 59.1 (3.8) 62.6 (6.6) 61.0 (5.6)
Body surface area (m2) 1.93 (0.21) 1.89 (0.13) 1.92 (0.10) 2.01 (0.17) 1.97 (0.15)
ECD (μg/L) 12.7 (1.8) 11.8 (2.1) 11.4 (1.5) 11.3 (1.8) 11.8 (1.8)
Mean (SD) demographics per treatment arm
LBM lean body, BSA body surface area, ECD HER2 extracellular domain
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Thus, drug product as covariate did not significantly improve
model fit. All PK parameter estimates obtained with the best
fit of the models are listed in Table 2.
Additionally, the rates of the linear and non-linear
elimination pathway vs. serum concentration trastuzumab
were calculated. At low serum concentrations of trastuzumab
(<10 μg/mL), total elimination was almost independent of
serum drug concentration, i.e. the non-linear elimination
exceeded the linear elimination. At high concentrations, this
pathway became saturated and the influence of non-linear
elimination seemed negligible (Online Resource Fig. 3).
Also, a more complex mechanistic model approach was
applied to characterise the distribution and clearance of
trastuzumab: the target-mediated drug disposition (TMDD)
model [17, 18]. Besides receptor and drug-receptor complex
quantification, such models are able to provide information on
binding affinity of the drug to the receptor. Fitting the TMDD
model to our data proved difficult due to over-parameteriza-
tion. A simplified approximation TMDD model approach
with a dissociation constant Kd [19] still resulted in an
incorrect fit and instability of the model, and the TMDD
model approach was abandoned.
Second step: separate models
Model development of the separate models, including only
data from participants whowere exposed to 6mg/kg, followed
a similar approach as the combined model to ensure the
structural similarity. For both trastuzumab products, a third
compartment could be identified, as well as a linear and a
non-linear route of elimination, described by Michaelis-
Menten kinetics.
For the separate models, individual estimates of random
effects for the between-subject variability were identified for
the parameters V1, Vmax and ke, with final coefficient of
variation values in model T of 16.5, 12.8 and 19 %,
respectively. The residual coefficient of variation of the best
model was 14.5 %. In model R, the final coefficients of
variation were 11.1, 18.8 and 17 %, with a residual coefficient
of variation of 14.1 %.
Similarly to the combined model, the best model fit with
the greatest reduction in OFV for both separate models was
obtained by incorporating LBWas linear covariate on V1 and
BMI on ke.
Model evaluation and predictive performance
Combined model
Goodness-of-fit plots of the combined model (Fig. 2) show
that all predictions lie around the line of unity. There was one
outlier in the reference group, where one subject had a very
low mid-infusion concentration of 0.088 μg/mL. Virtually all
Table 2 Population PK
parameters estimates from the full
covariate model for trastuzumab
Combined model Separate model T Separate model R
Parametera Estimate (CI)
Fixed effects
V1 (L) 3.28 (3.185–3.367) 3.59 (3.418–3.752) 3.13 (3.028–3.232)
V2 (L) 1.89 (1.325–2.457) 6.82 (−5.572–19.21) 44 (28.18–59.77)
V3 (L) 1.96 (1.736–2.179) 2.15 (1.858–2.443) 2.09 (1.929–2.244)
Q1 (L h−1) 2.91 (2.02–3.79) × 10−3 2.82 (1.081–4.566) 3.92 (3.58–4.25) × 10−3
Q2 (L h−1) 4.34 (3.66–5.01) × 10−2 3.75 (2.787–4.706) 4.67 (4.12–5.21) × 10−2
Vmax (μg h
−1) 178 (162.3–193.1) 172 (138.6–205.7) 127 (111–143.4)
KM (μg L
−1) 937 (759.6–1115) 995 (674.6–1316) 1440 (1189–1699)
Ke (h
−1) 2.20 (2.02–2.38) × 10−3 1.95 (1.33–2.57) × 10−3 1.76 (1.62−1.9) × 10−3
Random effects Estimate (CV%)
Between-subject variability
ω2 V1 0.0217 (14.8) 0.0270 (16.5) 0.0122 (11.1)
ω2 Vmax – 0.0163 (12.8) 0.0347 (18.8)
ω2 KM 0.121 (35.9) – –
ω2 ke 0.0292 (17.2) 0.0355 (19.0) 0.0286 (17.0)
Residual error
σ2 proportional 0.0222 0.0207 0.0198
σ2 additive 1520 3090 790
a Explanation of parameters is given in Fig. 1
CI confidence interval, CV coefficient of variation, ω2 between-subject variance, σ2 residual variance
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conditional weighted residuals with interaction (CWRESI) lie
randomly scattered around zero without apparent bias.
The variability of the parameters V1, KM and ke on the Eta
density histograms (Online Resource Fig. 4) seemed normally
distributed around zero with acceptable coefficient of
variation values, indicating correct description of the
between-subject variability. Furthermore, no significant
shrinkage was observed for parameters for which between-
subject variability was identified (<8.04 %).
The visual predictive check (VPC) proofs good predictive
performance (Fig. 3) of the combined model. For the doses
>1.48 mg/kg, no signs of bias were apparent and most
observations lay within the 95 % prediction interval (PI).
Only for the lowest dose administered (0.49 mg/kg), a slightly
higher prediction of the population mean was observed,
especially in the lower concentration range. However, even
for this dose group, most of the observations were within the
95 % prediction interval.
Separate models
The goodness-of-fit plots of the separate models (Online
Resource Figs. 1–2) show that predictions lie around the line
of unity and that the CWRESI are observed near the central
line. No bias or trend in the model prediction could be
determined. The shrinkage observed for the parameters for
which between-subject variability was identified (V1, Vmax,
ke) is not significant (<17.80 % for model T, <15.50 % for
model R). Additionally, the variability on the eta density
histograms (Online Resource Figs. 5–6) seemed normally
distributed around zero.
The population PK parameter estimates from the full
covariate model is presented in Table 2. When comparing
parameter estimates, most parameter distributions overlap.
The parameter estimates for V2 differ between model T and
model R, but are in the same order of magnitude. However,
Q1 and Q2 for model Twere higher compared to model R. In
contrast to the combined model, where between-subject
variability was identified for V1, KM and ke, in the separate
models, these were found for V1, Vmax and ke.
Comparison to NCA
The geometric mean (GM) AUClast obtained from the stan-
dard NCA was 1301 μg day−1 mL−1 for the test (T) and
1588 μg day−1 mL−1 for the reference (R) product. The
AUClast remained virtually unchanged when the same calcu-
lations were repeated with simulated concentrations, regard-
less of whether the combined model or the separate models
were used (Table 3). Similar results were obtained with regard
to AUCinf.
The GM ratio (GMR) T/R with all AUC methods was
81.66–82.54 % with the lower limit (LL) of the associated
90 % confidence interval (CI) below the predefined
equivalence boundary of 80 % (Table 3). Applying a linear
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Fig. 2 Goodness-of-fit plots
combined model. Observed vs.
population predicted




interaction (CWRESI) vs. time
(c), and conditional weighted
residuals vs population
predictions (d) of the combined
model
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AUClast and AUCinf to decrease (GMR T/R 89.11–89.55 %,
LL 90 % CI >84.66 %). Further reductions were achieved
when an equal dosage of 6 mg/kg was simulated for both
trastuzumab products, which affected the AUCs in the
reference product arm more profoundly and increased the
GMR with approximately 2 % point (Table 4).
Using the entire simulated profile, as opposed to only the
simulated concentrations at the original sampling times,
generally resulted in a small decrease of 1–2% compared with
the NCA for both AUClast and AUCinf, with the exception of
the AUCinf calculated on profiles derived with model R,
where an average increase of 1.7 % was observed (Online
Resource Tables 1 and 2). Conversely, with the combined
model, lower AUCs were obtained compared with the
separate models for T only.
Discussion
As long as generic products are being developed, controversy
and scepticism regarding the claims of therapeutic equality
have followed marketed bioequivalent products. Recently,
Bate et al. [20] advocated that for the more complex
pharmaceuticals, two allegedly bioequivalent drug products
may not be interchangeable, which could have adverse
consequences. MAbs are certainly among the most complex














































































































































































Fig. 3 Visual predictive check (VPC). Visual predictive check (VPC) of
the best combined model, conditioned per dose test product (0.49, 1.48,
2.96, 5.92 mg/kg) or reference product (6.44 mg/kg). The dots indicate
the observations for the different trastuzumab doses administered, the
lines are the typical predicted concentrations by the model for each
dose and the grey area is the 95 % prediction interval (PI). The dotted
line is the assay’s lower limit of quantification (LLOQ) for trastuzumab
(0.060 μg/mL)
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therapeutics, and establishing similarity to the reference
product can thus be challenging.
For demonstrating pharmacokinetic biosimilarity in a
human population, a NCA is virtually always performed and
its results (AUC andCmax) compared statistically, even though
it is widely recognised that the NCA is less suitable for drugs
with complex non-linear kinetics, as is the case for MAbs.
Population approach pharmacokinetic (PK) modelling and
simulation techniques have been successfully applied to
quantitatively describe the PK of MAbs in humans [21–26].
Such an approach has been applied in bioequivalence studies
and also for biotherapeutics [9], where it was found to give
indistinguishable results on the standard NCA parameters
(AUC and Cmax), as was the case in our analysis. However,
as was also argued by Dubois et al. [9], a PK model can
provide valuable insight in the biological systems underlying
the PK properties. Although the standard NCA-derived
parameters, such as Cmax, AUCinf, terminal half-life, etc.,
may seem similar, the two drug products could behave quite
differently in terms of PK, a feature that goes undetected in a
NCA [27]. Furthermore, similar plasma concentrations do not
invariably mean similar concentrations at the site of action.
Here, we describe two methods of incorporating PK
modelling in biosimilarity research. The first approach is
developing a model on all available data from both test and
reference product(s) and carefully examining possible bias in
one of the treatment groups. Testing for (statistically)
significant differences between drug product can be done for
all the model parameters via covariate analysis. Covariate
testing follows a well-established statistical distribution that
can be used for statistical inference [28, 29]. If no significant
correlations can be identified between the drug products and if
attempts to incorporate treatment as covariate in the model fail
to improve it, the biosimilarity claim is supported.
The second method entails the development of different
models, one for each test and reference product(s), which in
contrast to a combined model does not assume similarity
between test and reference product as a starting point. This
method allows comparison of the model structure that should
be identical for biosimilar products and of model parameters
for both test and reference product.
Comparing different PK models inevitably reveals minor
differences for which the clinical significance needs to be
discussed. For example, in model T, the optimal
inter-compartmental clearances (Q1 and Q2) were estimated
to be a factor 102–103 higher than the corresponding
parameters in the other models, while the striking dissimilarity
did not seem to affect the descriptive properties of the overall
profiles. However, as the (fictive) second and third
compartments were not sampled, this finding merely reflects
a mathematical solution to a rather complex problem and not
necessarily a true (e.g. physiological or pharmacological)
difference. Additionally, the higher dose administered for the
reference product could have allowed a better characterisation
of the terminal portion of the PK profile (elimination
parameters), which also affects the estimation of remaining
parameters such as Q1 and Q2.
This represents an important limitation of the second
method, which may be of particular relevance when
modelling PK data from two different populations separately.
Unfor tunately, pharmacokinet ic biosimilar i ty of
biotherapeutics is regularly investigated in trials of parallel
design, because of the long half-life and the potential of anti-
drug antibodies development, which could influence the phar-
macokinetics [30]. Theoretically, all MAbs share
common pharmacokinetic properties, e.g. small central
volume of distribution, no renal excretion due to large
molecular size, metabolism into amino acids and peptides,
both specific (non-linear) and non-specific (linear) cellular
uptake and degradation elimination mechanisms [31–35].
Thus, the remaining variability is probably determined by
Table 4 AUC comparison after dose correction
GM GM ratio (%)
AUClast Test Reference T/R
NCA 1318 1479 89.11 (84.66–93.79)
Separate models 1323 1455 90.93 (86.72–95.35)
Combined model 1319 1443 91.41 (87.25–95.76)
AUCinf
NCA 1329 1484 89.55 (85.03–94.30)
Separate models 1337 1457 91.74 (87.46–96.24)
Combined model 1324 1446 91.54 (87.37–95.92)
Geometric mean (GM) (μg day−1 mL−1 ) andGM ratio (%) with the 90%
confidence for the labelled dose (6 mg/kg) as derived by different
methods per treatment arm. For the NCA results, a linear dose correction
was applied; in the models, the labelled dose was used to simulate the
individual profiles (see main body)
T test, R reference
Table 3 AUC comparison actual dose
GM GM ratio (%)
AUClast Test Reference T/R
NCA 1301 1588 81.91 (77.82–86.22)
Separate models 1300 1588 81.86 (78.08–85.82)
Combined model 1296 1588 81.59 (77.88–85.47)
AUCinf
NCA 1311 1593 82.32 (78.17–86.69)
Separate models 1313 1591 82.54 (78.70–86.57)
Combined model 1300 1592 81.66 (77.93–85.56)
Geometric mean (GM) (μg day−1 mL−1 ) andGM ratio (%) with the 90%
confidence for the actual dose (test 5.92 mg/kg; reference 6.44 mg/kg) as
derived by different methods per treatment arm
T test, R reference
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patient characteristics.When comparing the model parameters
of the separate models, one of the most prominent differences
is the population estimate for V1, which is unlikely caused by
a difference between test and reference product.
The combined model equally well described the data,
without bias in either the test or reference group. Adding
trastuzumab drug product as covariate to the model could
not explain any residual variability, which not only strongly
supports the biosimilarity claim but also indicates that the
difference in AUCs must be attributed to population
characteristics.
From a regulatory perspective, another limitation of the
secondmethod is the lack of proper statistical inference testing
on the model parameters. One might consider overlapping
confidence intervals for parameter estimates indications for
biosimilarity, but many parameters are related, so that for
example a low inter-compartmental clearance may be
‘compensated’ in the model by a low volume of distribution.
An extension of ‘bioequivalence statistics’ has been applied to
model parameters by Wilkens et al. [36], although their
method suffers from the aforementioned limitations as well.
Notwithstanding the limitations of PPK, it has several
benefits over a NCA. Importantly, a PPK is not concerned
with differences in administered doses. Although EMA allows
a dose correction in the bioequivalence guideline (for
chemically-derived products) if the difference exceeds 5 %,
the NCA assumes linearity in its correction, which is not ap-
propriate for MAbs, that display non-linear pharmacokinetics.
Other benefits of PPK include the possibility to identify and
thus correct for certain covariates and the relative robustness
of a PPK against protocol deviations, with regard to timing of
sample collection, missing samples, duration of intravenous
administration and incomplete administration [8, 37].
Simulations with model R revealed that the two allowed
extremes for protein content per batch (effective dose 5.28 and
7.2 mg/kg) would result in a 90%CI for the GMR for AUClast
of 146.39–147.22 % in a cross-over design (n = 46). If such
batch-to-batch variations are not considered relevant, then the
consequences on the standard biosimilarity parameters may
also be argued to be irrelevant.
With a PK model, multiple scenarios can be simulated
within these extremes, which can be used to build the case
that the test product achieves therapeutic drug concentrations,
similar to the reference product, when administered according
to a certain dosing regimen. This approach also circumvents
some of the aforementioned limitations of direct comparison
of two or more models. If a biomarker or pharmacological
effect can be measured in the biosimilarity trial and
incorporated in a pharmacokinetic-pharmacodynamic model
(pharmacodynamic model), a relevant clinical target may be
simulated and lend further support to a biosimilarity claim.
The NCA will most likely remain a gold standard in
biosimilarity research, even for the complex MAbs.
Nonetheless, the model approach can serve as an elegant
add-on. Questions that need to be addressed before a PPK
can fully substitute the NCA in demonstrating biosimilarity
relate to selection of the most meaningful PK or pharmacody-
namic parameter from the model, and the minimal population
size to detect with sufficient statistical power relevant (model)
differences.
Previously, the benefits of modelling and simulation have
been proposed for proof of biosimilarity, to which this paper
adds similar benefits for MAbs.
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